IN2014DN10670A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10670A
IN2014DN10670A IN10670DEN2014A IN2014DN10670A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A IN 10670DEN2014 A IN10670DEN2014 A IN 10670DEN2014A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A
Authority
IN
India
Prior art keywords
compound
treating
formula
methods
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
I Robert Silverman
Julie F Liu
Adam J Morgan
Bhaumik Pandya
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2014DN10670A publication Critical patent/IN2014DN10670A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN10670DEN2014 2012-06-15 2013-06-14 IN2014DN10670A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02
PCT/US2013/045919 WO2013188783A1 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Publications (1)

Publication Number Publication Date
IN2014DN10670A true IN2014DN10670A (ru) 2015-08-28

Family

ID=48699982

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10670DEN2014 IN2014DN10670A (ru) 2012-06-15 2013-06-14

Country Status (11)

Country Link
EP (3) EP3450434B1 (ru)
AU (3) AU2013274030B2 (ru)
BR (1) BR122023027277A2 (ru)
CA (1) CA2876306C (ru)
DK (1) DK3450434T3 (ru)
EA (1) EA201492287A1 (ru)
ES (1) ES2867048T3 (ru)
IN (1) IN2014DN10670A (ru)
MX (1) MX360495B (ru)
PL (1) PL3450434T3 (ru)
WO (1) WO2013188783A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
AU2017378398B2 (en) * 2016-12-14 2023-02-02 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
WO2019113487A1 (en) * 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2020163653A1 (en) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
JP2024532765A (ja) 2021-08-12 2024-09-10 サン ファーマシューティカル インダストリーズ,インコーポレイテッド Jak阻害剤のプロドラッグを用いたjak阻害応答性障害の治療
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
JP4101661B2 (ja) 2001-05-03 2008-06-18 エフ.ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
UA98449C2 (en) * 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2242493B1 (en) 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
MY191357A (en) * 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib

Also Published As

Publication number Publication date
EP3882249A1 (en) 2021-09-22
WO2013188783A1 (en) 2013-12-19
ES2867048T3 (es) 2021-10-20
AU2018271227B2 (en) 2020-08-27
WO2013188783A8 (en) 2014-02-27
EP3450434A1 (en) 2019-03-06
MX360495B (es) 2018-11-06
PL3450434T3 (pl) 2021-10-04
AU2013274030B2 (en) 2016-07-07
AU2018271227A1 (en) 2018-12-13
AU2013274030A1 (en) 2015-01-22
BR122023027277A2 (pt) 2024-01-23
AU2016238877B2 (en) 2018-08-30
EP3450434B1 (en) 2021-02-24
EP2861600A1 (en) 2015-04-22
DK3450434T3 (da) 2021-05-03
EA201492287A1 (ru) 2015-07-30
BR112014031204A2 (pt) 2017-06-27
CA2876306C (en) 2024-02-20
AU2016238877A1 (en) 2016-10-27
CA2876306A1 (en) 2013-12-19
MX2014015185A (es) 2015-02-17

Similar Documents

Publication Publication Date Title
IN2014DN10670A (ru)
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2015DN01156A (ru)
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014MN02598A (ru)
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2015DN00598A (ru)
MX2015002040A (es) Baricitinib deuterado.
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
GB201106750D0 (en) Novel compounds
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MX362879B (es) Usos novedosos.
IN2014DN06869A (ru)
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
IN2014DN07996A (ru)
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201270728A1 (ru) Пуриновые соединения
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IN2014DN03010A (ru)
PH12016500809B1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
TN2013000515A1 (en) Notch pathway signaling inhibitor compound